HopeStage
Back to all studies
CompletedNCT00566735

Galantamine or placebo for thinking and memory changes after ECT

About this titleRead the official source — NCT00566735
Medication studyAges 18–90United StatesDepression
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 90 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2004
Recruitment status
Completed
Enrollment listed in the registry
39
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 90 Years
Official registry ID
NCT00566735
Official title
Show the full official title

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Razadyne and Placebo.

Who was this study for?

Listed age limits: 18 years to 90 years.

Want to explore more studies?

Explore studies